Generic form of antibiotic for CF lung infections wins FDA approval

Ritedose expands portfolio with new FDA-approved antibiotic

​ FDA approves Ritedose to produce a new inhalation antibiotic. Drug targets serious bacterial infections in patients 6 and older. Company now offers the largest nebulized drug portfolio in the U.S. Expansion supports domestic sterile manufacturing and supply chain resilience. A Midlands pharmaceutical manufacturer is adding to its product lineup. The U.S. Food and Drug Administration has approved The Ritedose Corp.’s manufacturing and dis…

Generic form of antibiotic for CF lung infections wins FDA approval

The U.S. Food and Drug Administration (FDA) has approved a new generic form of inhaled tobramycin, an antibiotic that’s used to treat bacterial lung infections in people with cystic fibrosis (CF). The newly approved therapy, tobramycin inhalation solution, will be sold by The Ritedose Corporation through its generics division, Ritedose Pharmaceuticals. It is indicated to treat Pseudomonas aeruginosa infections in CF patients ages 6 and older. “W…